# US 2025/0059208 A1 · Kras modulating compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0059208 A1
- Document ID: US20250059208A1
- Status: Published application
- Kind: A1
- Application number: 18/756,314
- Filed: 2024-06-27
- Published: 2025-02-20
- Earliest claimed: 2023-06-30
- Assignees: Gilead Sciences, Inc.
- Applicants: Gilead Sciences, Inc.
- Inventors: Wilian Augusto Cortopassi Coelho; Julie Farand; Michael Graupe; Juan A. Guerrero; Darryl Kato; Irene N. Kiburu; James B.C. Mack; Joshua L. Martin; Erik P. McAuley; Jonathan William Medley; Vickie H. Tsui; William J. Watkins
- Web page: https://patentgrep.com/patent/US20250059208A1

## CPC

- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are compounds, and pharmaceutically acceptable salts thereof, useful as KRAS inhibitors, methods of making and using the same (singly or in combination with additional agents), and pharmaceutical compositions thereof.

## Claims

### Claim 1

A compound of Formula (I):
or a pharmaceutically acceptable salt thereof,
wherein
X is N, CH, or CRx;
Rx is (CH2)mCN or halo;
m is 0, 1, 2 or 3;
each R3 and R4 is independently H or C1-C3 alkyl;
RA is phenyl, naphthyl, or 5- to 14-membered heteroaryl, wherein RA is substituted with 0, 1, 2, 3, 4, or 5 RA2;
each RA2 is independently —OH, C1-C10 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C10 alkoxy, C1-C10 hydroxyalkyl, C2-C10 alkoxyalkyl, C1-C6 alkyl-N(RA2a)(RA2b), C1-C10 thioalkyl, halo, C1-C6 haloalkyl, —CN, —C(O)RA2a, —C(O)ORA2a, —OC(O)RA2a, —OC(O)ORA2a, —C(O)N(RA2a)(RA2b), —N(RA2a)C(O)(RA2b), —OC(O)N(RA2a)(RA2b), —N(RA2a)C(O)(ORA2b), oxo, —ORA2a, —SRA2a, —S(O)2RA2a, —S(O)2ORA2a, —N(RA2a)(RA2b), —(C0-C3 alkyl)-SF5, —OP(O)(ORA2a)(ORA2b), C3-C8 cycloalkyl, —(C1-C6 alkyl)-(C3-C8 cycloalkyl), 3- to 14-membered heterocyclyl, —(C1-C6 alkyl)-(3- to 14-membered heterocyclyl), C6-C14 aryl, —(C1-C6 alkyl)-(C6-C14 aryl), 5- to 14-membered heteroaryl, or —(C1-C6 alkyl)-(5- to 14-membered heteroaryl), wherein each alkyl, alkenyl, alkynyl, alkoxy, hydroxyalkyl, and haloalkyl is substituted with 0, 1, 2, or 3 RA3, and wherein each cycloalkyl, alkyl-cycloalkyl, heterocyclyl, alkyl-heterocyclyl, aryl, alkyl-aryl, heteroaryl, and alkyl-heteroaryl is substituted with 0, 1, 2, or 3 RA4;
each RA2a and RA2b is independently H, C1-C10 alkyl, C1-C6 haloalkyl, or C3-C8 cycloalkyl;
each RA3 is independently halo, —CN, —ORA3a, —SRA3a, —N(RA3a)(RA3b), C3-C8 cycloalkyl, or 5- to 14-membered heteroaryl;
each RA3a and RA3b is independently H, C1-C10 alkyl, C1-C6 haloalkyl, or C3-C8 cycloalkyl;
each RA4 is independently C1-C6 alkoxy, C1-C6 hydroxyalkyl, C2-C6 alkoxyalkyl, C1-C6 haloalkyl, C1-C6haloalkoxy, C1-C6 haloalkylthio, C3-C8 cycloalkyl, —(C1-C6 alkyl)-(C6-C10 aryl), halo, —CN, —OH, or —N(RA4a)(RA4b);
each RA4a and RA4b is independently H or C1-C6 alkyl;
alternatively, two RA2 can combine to form a C3-C10 cycloalkyl, C6-C10 aryl, a 3- to 10-membered heterocyclyl, or 5- to 14-membered heteroaryl on two adjacent atoms on RA, wherein each cycloalkyl, aryl, heterocyclyl, and heteroaryl is substituted with 0, 1, 2, or 3 RA5;
each RA5 is independently C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, halo, C1-C6 haloalkyl, —CN, or C3-C8 cycloalkyl;
RB is H;
LC is a bond or
Y is C or Si;
n is 0, 1, 2, or 3;
q is 0, 1, 2, or 3;
RY1 is H or C1-C3 alkyl;
RY2 is H or C1-C3 alkyl;
alternatively, RY1 and RY2 combine to form a C3-C10 cycloalkyl or a 3- to 10-membered heterocyclyl;
RC is H, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C2-C6 alkoxyalkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, —NH2, —NHRC1, —N(RC1)2, C3-C8 cycloalkyl, 3- to 14-membered heterocyclyl, C6-C14 aryl, or 5- to 14-membered heteroaryl, wherein each C3-C8 cycloalkyl, 3- to 14-membered heterocyclyl, C6-C14 aryl, and 5- to 14-membered heteroaryl is substituted with 0, 1, 2, 3, or 4 RC3;
each RC1 is independently selected from C1-C6 alkyl;
each RC3 is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C8 alkynyl, C1-C6 alkoxyalkyl, C1-C6 hydroxyalkyl, halo, C1-C6 haloalkyl, C1-C6 heteroalkyl, —(C1-C6 alkyl)-N(RC3a)(RC3b), —CN, —C(O)RC3a, —C(O)ORC3a, —C(O)N(RC3a)(RC3b), —N(RC3a)C(O)(RC3b), —OC(O)N(RC3a)(RC3b), —N(RC3a)C(O)(ORC3b), ═CH2, ═CHF, ═CF2, oxo, —ORC3a, —SRC3a, —N(RC3a)(RC3b), —N3, SF5, C3-C8 cycloalkyl, —(C1-C6 alkyl)-(C3-C8 cycloalkyl), 3- to 10-membered heterocyclyl, —(C1-C6 alkyl)-(3- to 10-membered heterocyclyl), C6-C10 aryl, —(C1-C6 alkyl)-(C6-C10 aryl), 5- to 10-membered heteroaryl, or —(C1-C6 alkyl)-(5- to 10-membered heteroaryl), wherein each alkyl is substituted with 0, 1, 2, or 3 —CN, —C(O)ORC3a1, —C(O)N(RC3a1)(RC3a2), —N(RC3a1)C(O)(RC3a2), —OC(O)N(RC3a1)(RC3a2), —ORC3a1, —SRC3a1, N3, SF5, or 3- to 10-membered heterocyclyl substituted with 0, 1, 2, or 3 RC3a2, each cycloalkyl, alkyl-cycloalkyl, heterocyclyl, alkyl-heterocyclyl, aryl, alkyl-aryl, heteroaryl, and alkyl-heteroaryl is substituted with 0, 1, 2, or 3 halo, —CN, or RC3a2 each alkenyl is substituted with 0, 1, 2, or 3 halo, and each alkoxyalkyl and alkynyl is substituted with 0, 1, 2, or 3 C1-C6 alkyl, C1-C6 haloalkyl, C3-C8 cycloalkyl substituted with 0 or 1 C1-C6 haloalkyl, C6-C10 aryl, or 5- to 10-membered heteroaryl;
each RC3a and RC3b is independently H, C1-C10 alkyl, C1-C6 haloalkyl, C6-C10 aryl, C3-C6 cycloalkyl, 3- to 6-membered heterocyclyl, or 5- to 10-membered heteroaryl, wherein each aryl and heteroaryl is substituted with 0, 1, 2, or 3 halo, —CN, or RC3a2;
alternatively, RC3a and RC3b together with the N to which they are attached form a 3- to 8-membered heterocycle;
each RC3a1 and RC3a2 is independently C1-C3 alkyl, halo, C1-C6 haloalkyl, C3-C8 cycloalkyl, —(C1-C3 alkyl)-(C3-C8 cycloalkyl), 3- to 10-membered heterocyclyl, —(C1-C3 alkyl)-(3- to 10-membered heterocyclyl), C6-C10 aryl, —(C1-C3 alkyl)-(C6-C10 aryl), —(C2-C4 alkynyl)-(C6-C10 aryl), 5- to 10-membered heteroaryl, —(C1-C3 alkyl)-(5- to 10-membered heteroaryl), or SF5, wherein each cycloalkyl, alkyl-cycloalkyl, heterocyclyl, alkyl-heterocyclyl, aryl, alkyl-aryl, alkynyl-aryl, heteroaryl, and alkyl-heteroaryl is substituted with 0, 1, 2, or 3 halo, C1-C3 haloalkyl, C1-C3 haloalkoxy, or SF5;
alternatively, RC3a1 and RC3a2 together with the N to which they are attached form a 3- to 8-membered heterocycle;
RD is halo;
each heterocyclyl has 1, 2, 3, or 4 heteroatoms selected from N, O, S, and Si; and
each heteroaryl has 1, 2, 3, or 4 heteroatoms selected from N, O, and S.

### Claim at position 2

-3. (canceled)

### Claim 4 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, having the structure of Formula (I-1):

### Claim 5 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X is N.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X is C—F.

### Claim at position 7

-16. (canceled)

### Claim 17 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein RA is

### Claim at position 9

-23. (canceled)

### Claim 24 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein LC is —CH2—.

### Claim 25 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein
RC is 8- to 14-membered heterocyclyl, is substituted with 0, 1, 2, or 3 RC3;
each RC3 is independently C1-C6 alkyl, halo, ═CH2, ═CHF, —ORC3a, or —(C1-C6 alkyl)-(5- to 10-membered heteroaryl),
wherein each alkyl is substituted with 1 —OC(O)N(RC3a1)(RC3a2), —ORC3a1, or N3;
each RC3a is independently C1-C6 haloalkyl; and
each RC3a1 and RC3a2 is independently C1-C3 alkyl, C1-C6 haloalkyl, or C6-C10 aryl, wherein each aryl is substituted with 1 SF5;
alternatively, RC3a1 and RC3a2 together with the N to which they are attached form a 3- to 8-membered heterocycle.

### Claim at position 12

-29. (canceled)

### Claim 30 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the —O-LC-RC moiety is

### Claim 31 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein RD is F.

### Claim 32 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein
X is N, CH, C—F, or C—Cl;
R3 and R4 are each H;
RA is
RB is H;
the —O-LC-RC moiety is
and
RD is F.

### Claim 33 (depends on 32)

The compound of claim 32, or a pharmaceutically acceptable salt thereof, wherein RA is

### Claim 34 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein
X is N;
R3 and R4 are each H;
RA is naphthyl, wherein RA is substituted with 2 RA2;
each RA2 is independently C2-C6 alkynyl or halo;
LC is
Y is C;
n is 0;
q is 0;
RY1 is H;
RY2 is H;
RC is 3- to 14-membered heterocyclyl, wherein the 3- to 14-membered heterocyclyl is substituted with 1 RC3;
RC3 is C1-C6 alkyl, halo, or C1-C6 haloalkyl, wherein the alkyl is substituted with 1 —ORC3a1;
RC3a1 is 5- to 10-membered heteroaryl, wherein the heteroaryl is substituted with 1 C1-C3 haloalkyl; and
RD is F.

### Claim 35 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein
X is N;
R3 and R4 are each H;
RA is
the —O-LC-RC moiety is
and
RD is F.

### Claim 36 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, having the structure of Formula (Ia-1) or Formula (Ia-2):
wherein
RC3 is —CH2ORC3a1 or F; and
RC3a1 is 5- to 6-membered heteroaryl substituted with one halo or C1-C2 haloalkyl.

### Claim 37 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, having the structure of Formula (Ia-3) or Formula (Ia-4):
wherein
RC3 is —CH2ORC3a1 or F; and
RC3a1 is 5- to 6-membered heteroaryl substituted with one halo or C1-C2 haloalkyl.

### Claim 38 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has the structure:

### Claim at position 22

-49. (canceled)

### Claim 50 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, and a pharmaceutically acceptable excipient.

### Claim 51 (depends on 50)

The pharmaceutical composition of claim 50, further comprising one or more additional therapeutic agents.

### Claim 52 (depends on 1)

A method of inhibiting KRAS G12D protein in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 1.

### Claim 53 (depends on 1)

A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 1.

### Claim at position 27

-93. (canceled)
